Skip to main content
EVIDENCE-BASED MEDICINE

Evidence-Based Mental Health Use of Anticonvulsants During Pregnancy

Psychopharmacology Bulletin 37(2): 59-66, 2003/04/15; https://doi.org/10.64719/pb.4184

Abstract

There are many pertinent issues surrounding the treatment of bipolar disorder during pregnancy. Unfortunately, while there are numerous observational reports in the literature, there is limited information concerning the safety and efficacy of particular treatments or the nontreatment of bipolar disorder during pregnancy. Much of the existing data comes from the neurology literature regarding epilepsy. In this review, we summarize the available evidence regarding the safety and efficacy of using the anticonvulsants carbamazepine and valproic acid during pregnancy. The available data suggest that there is a possibility of risk of major malformations with these anticonvulsants. The risk is probably higher with valproic acid than carbamazepine. In this article, lithium is not discussed, although there are concerns about lithium’s potential teratogenicity, and it has been implicated in Epstein’s anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations. Psychopharmacology Bulletin. 2003;37(2):59-66.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Jane P. Gagliardi, MD, and K. Ranga Rama Krishnan, MB, ChB. Evidence-Based Mental Health Use of Anticonvulsants During Pregnancy. Psychopharmacology Bulletin. 2003/04/15; 37(2):59-66. https://doi.org/10.64719/pb.4184